Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

Core Insights - Fractyl Health's Revita shows promising results for weight maintenance after GLP-1 therapy discontinuation, with significant weight regain reduction and improved cardiometabolic profiles at 6 months [1][2][3] Study Results - Revita-treated patients had a 4.5% weight regain compared to 7.5% in the sham group at 6 months, indicating a meaningful reduction in expected post-GLP-1 weight regain [7] - Patients with above median GLP-1-associated weight loss experienced approximately 70% less weight regain with Revita (4.2% vs 13.3% in sham) [7] - Improvements in cardiometabolic parameters included increased HDL cholesterol (15.5 mg/dL vs 3.9 mg/dL) and reduced triglyceride-to-HDL ratio (-0.2 vs +0.4) [7] - Patient-reported outcomes indicated a reduction in sweet-food cravings (1.8 vs 3.4) [7] Safety and Tolerability - Revita demonstrated excellent safety and tolerability, with no serious adverse events related to the device or procedure reported through six months [12] Regulatory Strategy - The company has requested FDA feedback on reclassifying Revita under the De Novo pathway, which may facilitate a more efficient regulatory review process [9] - Feedback from the FDA is expected in Q2 2026 [9] Future Milestones - Key upcoming milestones include the completion of randomizations in the REMAIN-1 Pivotal Cohort by February 2026, and the potential FDA marketing application submission in H2 2026 [13]